8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 1, 2026·SEC
Axsome Therapeutics, Inc.(AXSM)Earnings, Financials & Key Ratios
AXSM•NASDAQ
$222.63
$11.46B mkt cap·Price updated May 6, 2026
AboutAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Show more
- Revenue$638M+65.5%
- EBITDA-$160M+41.2%
- Net Income-$183M+36.2%
- EPS (Diluted)-3.68+38.6%
- Gross Margin92.56%+1.3%
- EBITDA Margin-25.09%+64.5%
- Operating Margin-26.51%+63.6%
- Net Margin-28.69%+61.5%
- ROE-252.11%-8.8%
- ROIC-1906.66%
- Debt/Equity2.73-19.2%
- Interest Coverage-27.02+36.7%
AXSM Key Insights
Axsome Therapeutics, Inc. (AXSM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 88 (top 12%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗High debt to equity ratio of 2.7x
- ✗Profits declining 12.2% over 5 years
- ✗Negative free cash flow
- ✗Expensive at 125.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AXSM Price & Volume
Axsome Therapeutics, Inc. (AXSM) stock price & volume — 10-year historical chart
Loading chart...
AXSM Growth Metrics
Axsome Therapeutics, Inc. (AXSM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years133.68%
TTM63.88%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM32.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM35.36%
Return on Capital
10 Years-94.92%
5 Years-84.16%
3 Years-63.7%
Last Year-52.12%
AXSM Recent Earnings
Axsome Therapeutics, Inc. (AXSM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 4, 2026EPS
$1.26
Est $0.85
-48.2%
Revenue
$189M
Est $191M
-0.9%
Q1 2026
Feb 23, 2026EPS
$0.71
Est $0.70
-1.4%
Revenue
$195M
Est $193M
+0.7%
Q4 2025
Nov 3, 2025EPS
$0.94
Est $0.82
-14.6%
Revenue
$171M
Est $191M
-10.6%
Q3 2025
Aug 4, 2025EPS
$0.92
Est $1.00
+8.0%
Revenue
$150M
Est $140M
+7.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $1.26vs $0.85-48.2% | $189Mvs $191M-0.9% |
| Q1 2026 | Feb 23, 2026 | $0.71vs $0.70-1.4% | $195Mvs $193M+0.7% |
| Q4 2025 | Nov 3, 2025 | $0.94vs $0.82-14.6% | $171Mvs $191M-10.6% |
| Q3 2025 | Aug 4, 2025 | $0.92vs $1.00+8.0% | $150Mvs $140M+7.2% |
Based on last 12 quarters of dataView full earnings history →
AXSM Peer Comparison
Axsome Therapeutics, Inc. (AXSM) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INTR | 2.54B | 7.84 | 18.70 | 27.12% | 12.37% | 1.31 | ||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 | |
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 |
Compare AXSM vs Peers
Axsome Therapeutics, Inc. (AXSM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AXSM Income Statement
Axsome Therapeutics, Inc. (AXSM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 50.04M | 270.6M | 385.69M | 638.5M | 708.24M |
| Revenue Growth % | - | - | - | - | - | - | 440.8% | 42.53% | 65.55% | 63.88% |
| Cost of Goods Sold | 42.56K | 48.94K | 37.33K | 0 | 0 | 5.2M | 26.07M | 33.3M | 47.48M | 52.41M |
| COGS % of Revenue | - | - | - | - | - | 10.39% | 9.63% | 8.63% | 7.44% | - |
| Gross Profit | -42.56K▲ 0% | -48.94K▼ 15.0% | -37.33K▲ 23.7% | 0▲ 100.0% | 0▲ 0% | 44.84M▲ 0% | 244.53M▲ 445.4% | 352.39M▲ 44.1% | 591.02M▲ 67.7% | 655.82M▲ 0% |
| Gross Margin % | - | - | - | - | - | 89.61% | 90.37% | 91.37% | 92.56% | 92.6% |
| Gross Profit Growth % | -107.76% | -14.99% | 23.72% | 100% | - | - | 445.36% | 44.11% | 67.72% | - |
| Operating Expenses | 27.16M | 32.85M | 67.11M | 99.14M | 124.71M | 224.64M | 476.36M | 632.95M | 760.25M | 831.43M |
| OpEx % of Revenue | - | - | - | - | - | 448.94% | 176.04% | 164.11% | 119.07% | - |
| Selling, General & Admin | 7.21M | 9.35M | 13.6M | 28.9M | 66.65M | 159.25M | 323.12M | 411.36M | 570.6M | 634.81M |
| SG&A % of Revenue | - | - | - | - | - | 318.27% | 119.41% | 106.65% | 89.37% | - |
| Research & Development | 19.96M | 23.5M | 53.65M | 70.24M | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M | 191.17M |
| R&D % of Revenue | - | - | - | - | - | 115.81% | 36.2% | 48.5% | 28.7% | - |
| Other Operating Expenses | 0 | 0 | -139.45K | -53.58K | 0 | 7.44M | 55.29M | 34.52M | 6.38M | 0 |
| Operating Income | -27.16M▲ 0% | -32.85M▼ 20.9% | -67.25M▼ 104.7% | -99.14M▼ 47.4% | -124.71M▼ 25.8% | -179.8M▼ 44.2% | -231.82M▼ 28.9% | -280.56M▼ 21.0% | -169.24M▲ 39.7% | -175.61M▲ 0% |
| Operating Margin % | - | - | - | - | - | -359.33% | -85.67% | -72.74% | -26.51% | -24.8% |
| Operating Income Growth % | 1.38% | -20.92% | -104.72% | -47.43% | -25.79% | -44.18% | -28.94% | -21.02% | 39.68% | - |
| EBITDA | -27.12M | -32.8M | -67.21M | -99.06M | -124.63M | -175.4M | -224.99M | -272.6M | -160.17M | -167.09M |
| EBITDA Margin % | - | - | - | - | - | -350.53% | -83.15% | -70.68% | -25.09% | -23.59% |
| EBITDA Growth % | 1.46% | -20.93% | -104.92% | -47.4% | -25.81% | -40.73% | -28.28% | -21.16% | 41.24% | 36.23% |
| D&A (Non-Cash Add-back) | 42.56K | 48.94K | 37.33K | 77.72K | 76K | 4.4M | 6.83M | 7.96M | 9.06M | 8.52M |
| EBIT | -27.81M | -32.63M | -67.25M | -100.39M | -124.71M | -179.8M | -231.82M | -280.56M | -177.15M | -181.24M |
| Net Interest Income | -1.34M | -1.13M | 0 | 0 | -5.7M | -7.33M | -6.45M | -6.57M | 2.81M | -3.27M |
| Interest Income | 0 | 0 | 1.24M | 2.57M | 0 | 0 | 0 | 0 | 9.37M | 2.04M |
| Interest Expense | 1.34M | 1.13M | 1.24M | 2.57M | 5.7M | 7.33M | 6.45M | 6.57M | 6.56M | 5.31M |
| Other Income/Expense | -1.78M | 1.66M | -1.1M | -3.76M | -5.7M | -7.33M | -6.45M | -6.57M | -14.47M | -13.22M |
| Pretax Income | -28.94M▲ 0% | -30.97M▼ 7.0% | -68.35M▼ 120.7% | -102.9M▼ 50.6% | -130.4M▼ 26.7% | -187.13M▼ 43.5% | -238.28M▼ 27.3% | -287.13M▼ 20.5% | -183.7M▲ 36.0% | -188.83M▲ 0% |
| Pretax Margin % | - | - | - | - | - | -373.99% | -88.06% | -74.45% | -28.77% | -26.66% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 960K | 85K | -530K | -530K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -0.4% | -0.03% | 0.29% | 0.28% |
| Net Income | -28.94M▲ 0% | -30.97M▼ 7.0% | -68.35M▼ 120.7% | -102.9M▼ 50.6% | -130.4M▼ 26.7% | -187.13M▼ 43.5% | -239.24M▼ 27.8% | -287.22M▼ 20.1% | -183.17M▲ 36.2% | -188.3M▲ 0% |
| Net Margin % | - | - | - | - | - | -373.99% | -88.41% | -74.47% | -28.69% | -26.59% |
| Net Income Growth % | -6.4% | -6.99% | -120.71% | -50.56% | -26.73% | -43.5% | -27.84% | -20.05% | 36.22% | 32.33% |
| Net Income (Continuing) | -28.94M | -30.97M | -68.35M | -102.9M | -130.4M | -187.13M | -239.24M | -287.22M | -183.17M | -188.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.27▲ 0% | -1.15▲ 9.4% | -2.05▼ 78.3% | -2.83▼ 38.0% | -3.47▼ 22.6% | -4.60▼ 32.6% | -5.27▼ 14.6% | -5.99▼ 13.7% | -3.68▲ 38.6% | -3.68▲ 0% |
| EPS Growth % | 10.56% | 9.45% | -78.26% | -38.05% | -22.61% | -32.56% | -14.57% | -13.66% | 38.56% | 35.36% |
| EPS (Basic) | -1.27 | -1.15 | -2.05 | -2.83 | -3.47 | -4.60 | -5.27 | -5.99 | -3.68 | - |
| Diluted Shares Outstanding | 22.76M | 26.88M | 34.02M | 37.21M | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M | 51.2M |
| Basic Shares Outstanding | 22.76M | 26.88M | 34.02M | 37.21M | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M | 51.2M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AXSM Balance Sheet
Axsome Therapeutics, Inc. (AXSM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 35.3M | 15.22M | 220.38M | 184.02M | 86.52M | 245.64M | 504.26M | 485.06M | 588.99M | 611.21M |
| Cash & Short-Term Investments | 34.02M | 13.97M | 219.97M | 183.88M | 86.47M | 200.84M | 386.19M | 315.35M | 322.93M | 305.11M |
| Cash Only | 34.02M | 13.97M | 219.97M | 183.88M | 86.47M | 200.84M | 386.19M | 315.35M | 322.93M | 305.11M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 37.7M | 94.82M | 142M | 224.46M | 251.06M |
| Days Sales Outstanding | - | - | - | - | - | 275 | 127.9 | 134.38 | 128.32 | 112.2 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 4.32M | 15.13M | 15.73M | 27.94M | 31.52M |
| Days Inventory Outstanding | - | - | - | - | - | 303.35 | 211.94 | 172.42 | 214.78 | 177 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 2.78M | 8.12M | 11.98M | 13.65M | 23.52M |
| Total Non-Current Assets | 256.02K | 164.18K | 170.5K | 2.11M | 1.27M | 85.83M | 83.97M | 83.43M | 100.82M | 102.4M |
| Property, Plant & Equipment | 68.07K | 51.83K | 30.62K | 1.79M | 944.01K | 1.14M | 7.62M | 5.97M | 20.86M | 20.01M |
| Fixed Asset Turnover | - | - | - | - | - | 43.82x | 35.52x | 64.64x | 30.61x | 31.25x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 10.31M | 12.04M | 12.04M | 12.04M | 12.04M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 59.66M | 53.29M | 46.89M | 40.52M | 38.95M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 187.95K | 112.34K | 139.88K | 317.38K | 322.91K | 14.72M | 11.03M | 18.53M | 27.4M | 106.14M |
| Total Assets | 35.56M▲ 0% | 15.38M▼ 56.7% | 220.55M▲ 1334.1% | 186.13M▼ 15.6% | 87.79M▼ 52.8% | 331.48M▲ 277.6% | 588.24M▲ 77.5% | 568.5M▼ 3.4% | 689.8M▲ 21.3% | 713.61M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.15x | 0.46x | 0.68x | 0.93x | 1.04x |
| Asset Growth % | -6.95% | -56.75% | 1334.07% | -15.6% | -52.84% | 277.6% | 77.46% | -3.36% | 21.34% | 76.84% |
| Total Current Liabilities | 12.18M | 10.82M | 24.49M | 23.44M | 23.07M | 96.56M | 138.85M | 230.1M | 378.84M | 439.21M |
| Accounts Payable | 3.44M | 3.69M | 10.94M | 13.5M | 13.15M | 38.6M | 40.68M | 72M | 65.54M | 106.7M |
| Days Payables Outstanding | 29.46K | 27.5K | 107K | - | - | 2.71K | 569.65 | 789.09 | 503.83 | 553.78 |
| Short-Term Debt | 3.27M | 3.29M | 2.6M | 0 | 0 | 0 | 0 | 0 | 72.98M | 70.63M |
| Deferred Revenue (Current) | 2.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 444.29K | 0 | 0 | 0 | 4.05M | 17.18M | 76.45M | 36.51M | 203.28M | 261.88M |
| Current Ratio | 2.90x | 1.41x | 9.00x | 7.85x | 3.75x | 2.54x | 3.63x | 2.11x | 1.55x | 1.55x |
| Quick Ratio | 2.90x | 1.41x | 9.00x | 7.85x | 3.75x | 2.50x | 3.52x | 2.04x | 1.48x | 1.48x |
| Cash Conversion Cycle | - | - | - | - | - | -2.13K | -229.81 | -482.28 | -160.74 | -264.58 |
| Total Non-Current Liabilities | 6.66M | 3.62M | 17.33M | 48.9M | 49.09M | 125.36M | 258.4M | 281.38M | 222.67M | 219.81M |
| Long-Term Debt | 6.66M | 3.62M | 17.33M | 48.32M | 49.09M | 94.26M | 178.07M | 180.71M | 140.93M | 146.08M |
| Capital Lease Obligations | 0 | 0 | 0 | 581.71K | 0 | 0 | 7.04M | 8.99M | 27.39M | 82.53M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 31.1M | 73.3M | 91.68M | 54.36M | 297.61M |
| Total Liabilities | 18.84M | 14.44M | 41.83M | 72.34M | 72.15M | 221.92M | 397.26M | 511.48M | 601.51M | 659.02M |
| Total Debt | 9.93M | 6.91M | 19.93M | 50.12M | 49.71M | 94.68M | 186.37M | 192.96M | 241.29M | 216.71M |
| Net Debt | -24.09M | -7.06M | -200.03M | -133.75M | -36.76M | -106.16M | -199.82M | -122.4M | -81.64M | -88.4M |
| Debt / Equity | 0.59x | 7.37x | 0.11x | 0.44x | 3.18x | 0.86x | 0.98x | 3.38x | 2.73x | 2.73x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.30x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.53x |
| Interest Coverage | -20.75x | -28.94x | -54.25x | -39.12x | -21.89x | -24.51x | -35.93x | -42.71x | -27.02x | -34.13x |
| Total Equity | 16.72M▲ 0% | 937.92K▼ 94.4% | 178.72M▲ 18955.2% | 113.79M▼ 36.3% | 15.63M▼ 86.3% | 109.56M▲ 600.9% | 190.98M▲ 74.3% | 57.02M▼ 70.1% | 88.3M▲ 54.9% | 54.59M▲ 0% |
| Equity Growth % | -22.5% | -94.39% | 18955.16% | -36.33% | -86.26% | 600.92% | 74.32% | -70.15% | 54.86% | 7.87% |
| Book Value per Share | 0.73 | 0.03 | 5.25 | 3.06 | 0.42 | 2.69 | 4.20 | 1.19 | 1.77 | 1.07 |
| Total Shareholders' Equity | 16.72M | 937.92K | 178.72M | 113.79M | 15.63M | 109.56M | 190.98M | 57.02M | 88.3M | 54.59M |
| Common Stock | 2.55K | 3.01K | 3.69K | 3.74K | 3.78K | 4K | 5K | 5K | 5K | 5K |
| Retained Earnings | -76.58M | -107.55M | -175.9M | -278.8M | -409.2M | -596.33M | -835.57M | -1.12B | -1.31B | -1.37B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AXSM Cash Flow Statement
Axsome Therapeutics, Inc. (AXSM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -26.47M | -30.05M | -46.38M | -78.46M | -108.23M | -116.51M | -145.08M | -128.41M | -93.41M | -93.41M |
| Operating CF Margin % | - | - | - | - | - | -232.85% | -53.61% | -33.29% | -14.63% | - |
| Operating CF Growth % | -24.39% | -13.53% | -54.31% | -69.18% | -37.94% | -7.66% | -24.52% | 11.49% | 27.26% | 179.02% |
| Net Income | -28.94M | -30.97M | -68.35M | -102.9M | -130.4M | -187.13M | -239.24M | -287.22M | -183.17M | -188.3M |
| Depreciation & Amortization | 42.56K | 48.94K | 37.33K | 77.72K | 76K | 4.4M | 6.83M | 7.96M | 9.06M | 8.76M |
| Stock-Based Compensation | 2.07M | 1.75M | 6.12M | 14.76M | 20.8M | 37.73M | 62.62M | 0 | 93.75M | 70.44M |
| Deferred Taxes | 646K | -2.79M | 0 | 1.25M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 470.52K | 375.63K | 649.99K | 7.95M | 974K | 4.83M | 53.1M | 116.95M | 9.48M | 34.3M |
| Working Capital Changes | -759.55K | 1.52M | 15.17M | 412.04K | 324K | 23.67M | -28.39M | 33.9M | -22.52M | 4.07M |
| Change in Receivables | 0 | 0 | 0 | 177.5K | 0 | -37.7M | -57.12M | -47.18M | -82.46M | -89.67M |
| Change in Inventory | 0 | 0 | 0 | -177.5K | -6K | -5.28M | -8.16M | 744K | -15.67M | -13.37M |
| Change in Payables | -645.72K | 251.79K | 7.26M | 2.56M | -355K | 25.46M | 2.07M | 31.32M | -6.46M | 21.04M |
| Cash from Investing | -9.9K | -32.7K | -16.12K | -45.89K | -308K | -53.7M | -582K | -270K | -480K | -263K |
| Capital Expenditures | -9.9K | -32.7K | -16.12K | -45.89K | -308K | -702K | -582K | -270K | -480K | -263K |
| CapEx % of Revenue | - | - | - | - | - | 1.4% | 0.22% | 0.07% | 0.08% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -53M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 23.88M | 10.03M | 252.39M | 42.41M | 11.13M | 284.58M | 331.01M | 57.84M | 101.47M | 75.19M |
| Debt Issued (Net) | -277.78K | -3.33M | 12.76M | 28.34M | 0 | 45M | 85M | -990K | -7.75M | -8.02M |
| Equity Issued (Net) | 23.68M | 12.88M | 238.23M | 14.13M | 7.44M | 243.76M | 258.75M | 40.78M | 126.27M | 106.2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 484.61K | 486.03K | 1.39M | -52.76K | 3.69M | -4.18M | -12.74M | 18.05M | -17.05M | -22.99M |
| Net Change in Cash | -2.6M▲ 0% | -20.05M▼ 672.0% | 206M▲ 1127.3% | -36.09M▼ 117.5% | -97.4M▼ 169.9% | 114.37M▲ 217.4% | 185.35M▲ 62.1% | -70.84M▼ 138.2% | 7.58M▲ 110.7% | 4.2M▲ 0% |
| Free Cash Flow | -26.48M▲ 0% | -30.09M▼ 13.6% | -46.39M▼ 54.2% | -78.5M▼ 69.2% | -108.53M▼ 38.3% | -117.21M▼ 8.0% | -145.66M▼ 24.3% | -128.68M▲ 11.7% | -93.89M▲ 27.0% | -70.99M▲ 0% |
| FCF Margin % | - | - | - | - | - | -234.25% | -53.83% | -33.36% | -14.7% | -10.02% |
| FCF Growth % | -23.83% | -13.61% | -54.19% | -69.22% | -38.26% | -8% | -24.27% | 11.66% | 27.04% | 40.13% |
| FCF per Share | -1.16 | -1.12 | -1.36 | -2.11 | -2.89 | -2.88 | -3.21 | -2.69 | -1.89 | -1.89 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.97x | 0.68x | 0.76x | 0.83x | 0.62x | 0.61x | 0.45x | 0.51x | 0.38x |
| Interest Paid | 865.28K | 771.97K | 1.29M | 2.1M | 4.63M | 7.69M | 16.73M | 19.69M | 14.63M | 10.04M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AXSM Key Ratios
Axsome Therapeutics, Inc. (AXSM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -151.19% | -350.78% | -76.08% | -70.36% | -201.51% | -298.97% | -159.21% | -231.63% | -252.11% | -260.01% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | -1906.66% | -1906.66% |
| Gross Margin | - | - | - | - | - | 89.61% | 90.37% | 91.37% | 92.56% | 92.6% |
| Net Margin | - | - | - | - | - | -373.99% | -88.41% | -74.47% | -28.69% | -26.59% |
| Debt / Equity | 0.59x | 7.37x | 0.11x | 0.44x | 3.18x | 0.86x | 0.98x | 3.38x | 2.73x | 2.73x |
| Interest Coverage | -20.75x | -28.94x | -54.25x | -39.12x | -21.89x | -24.51x | -35.93x | -42.71x | -27.02x | -34.13x |
| FCF Conversion | 0.91x | 0.97x | 0.68x | 0.76x | 0.83x | 0.62x | 0.61x | 0.45x | 0.51x | 0.38x |
| Revenue Growth | - | - | - | - | - | - | 440.8% | 42.53% | 65.55% | 63.88% |
AXSM SEC Filings & Documents
Axsome Therapeutics, Inc. (AXSM) SEC filings — annual & quarterly reports (10-K, 10-Q)
AXSM Frequently Asked Questions
Axsome Therapeutics, Inc. (AXSM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Axsome Therapeutics, Inc. (AXSM) reported $708.2M in revenue for fiscal year 2025.
Axsome Therapeutics, Inc. (AXSM) grew revenue by 65.5% over the past year. This is strong growth.
Axsome Therapeutics, Inc. (AXSM) reported a net loss of $188.3M for fiscal year 2025.
Dividend & Returns
Axsome Therapeutics, Inc. (AXSM) has a return on equity (ROE) of -252.1%. Negative ROE indicates the company is unprofitable.
Axsome Therapeutics, Inc. (AXSM) had negative free cash flow of $71.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More AXSM
Axsome Therapeutics, Inc. (AXSM) financial analysis — history, returns, DCA and operating performance tools
Full AXSM Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates